Tetraphase Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$99M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Tetraphase Pharmaceuticals's estimated annual revenue is currently $1.9M per year.(i)
  • Tetraphase Pharmaceuticals received $6.9M in venture funding in July 2017.
  • Tetraphase Pharmaceuticals's estimated revenue per employee is $82,174
  • Tetraphase Pharmaceuticals's total funding is $99M.

Employee Data

  • Tetraphase Pharmaceuticals has 23 Employees.(i)
  • Tetraphase Pharmaceuticals grew their employee count by -39% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase's proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol TTPH. Tetraphase is well positioned to be a major player in the multidrug-resistant arena.

keywords:Biotechnology, Healthcare

$99M

Total Funding

23

Number of Employees

$1.9M

Revenue (est)

-39%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Tetraphase Pharmaceuticals News

2022-04-19 - Movers & Shakers: John Maraganore, Larry Alstiel, Brad ...

Ocuphire Pharma, Inc.: Jay Pepose was appointed chief medical adviser of ... as a chief operating officer of Tetraphase Pharmaceuticals.

2022-04-17 - Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases

... experience in the biotech and pharmaceutical industries to the company. ... as chief operating officer of Tetraphase Pharmaceuticals,...

2022-04-13 - Global Bacteriostatic Antibiotics Market 2022 Trend Analysis ...

They are the key players profiled in the global market report: Tetraphase Pharmaceuticals; Allergan; Pfizer; Mylan; Sun Pharmaceutical...

2020-03-16 - AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a Redwood City-based specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, is to acquire Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company usi ...

2020-03-16 - An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

Some four years af­ter it re­port­ed its first batch of piv­otal tri­al da­ta, Tetraphase fi­nal­ly se­cured FDA ap­proval for its lead an­tibi­ot­ic, er­ava­cy­cline, for com­pli­cat­ed in­tra-ab­dom­i­nal in­fec­tions in 2018. But like many of its peers, mere­ly se­cur­ing ap­proval was on­ly ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.7M25-31%N/A
#2
$5.3M260%N/A
#3
$3.9M274%N/A
#4
$2.9M31121%N/A
#5
$1.7M3119%N/A

Tetraphase Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2008-08-08$15.0MAMultipleArticle
2009-10-07$10.0MBArticle
2010-06-02$45.0MCExcel Venture ManagementArticle
2013-11-05$UndisclosedUndisclosedBMO Capital MarketsArticle
2013-11-08$45.0MUndisclosedArticle
2014-10-17$75.0MUndisclosedArticle
2014-10-24$86.3MUndisclosedArticle
2015-03-13$173.1MUndisclosedBMO Capital MarketsArticle
2017-07-28$6.9MUndisclosedPiper JaffrayArticle